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Abstract Abstract 
Background: Massive strides have been made with respect to primary and secondary 
prevention of human papillomavirus (HPV)-associated disease as a result of prophylactic 
vaccination and cervical screening based on molecular HPV testing. However, cervical cancer 
continues to be an important clinical and societal burden. Additionally, other HPV-associated 
cancers for which there are no screening programmes are rising. Finally, the optimal 
combination of vaccination and screening strategies will require careful thinking. Considering 
this unprecedented and important time, we were keen to solicit the views of the expert 
community to determine what they perceived were the key priorities for HPV research. Our 
objective was to identify consensus and key priorities for HPV-based research through provision 
of a questionnaire disseminated to a multidisciplinary group of key opinion leaders (KOLs). 
Summary: A structured survey composed of 46 HPV research “categories” was sent to 73 
KOLs who were invited to “rank” the categories according to priority. The invitees represented 
clinical and public health disciplines as well as basic scientists. Scores were weighted according 
to the number of responses. Invitees also had the opportunity to comment on barriers to the 
research and suggest other research areas that required attention not reflected in the survey. 
We received 29 responses in total; overall, the 3 highest-ranked categories were “optimal 
cervical screening in low and middle-income countries (LMICs),” “primary disease prevention in 
LMICs” and “impact of vaccine on HPV infection and associated disease.” “HPV and the 
microbiome” and “mechanisms of transformation” were the highest-ranked categories with 
  3 
 
 
respect to basic research. Consistent barriers to research were around governance on the use 
of samples and data and funding, particularly in an era of vaccination. Key Messages: 
Research to support the management of disease in LMICs is clearly perceived as a priority in 
the international community in addition to other diverse areas which necessitate an improved 
basic understanding of viral mechanisms and interactions. International, multidisciplinary efforts 
which articulate the broader HPV research agenda will be important when seeking funding in 
addition to international endeavours to support the efficient use of existing samples and cohorts 
to facilitate such research.
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Key Messages  
  
  
 
 
 
Body  
Introduction 
Unquestionably, this is an important and almost unprecedented time for human 
papillomavirus (HPV)-based research. Decades of ground-breaking work starting with the 
demonstration of a transmissible agent that could cause warts led to the confirmation that 
certain carcinogenic (high-risk) HPV types can cause cervical cancer [1–3]. More recently the 
research has translated into global primary and secondary disease prevention strategies, which 
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increasingly depend on HPV-based vaccination and testing [4]. In synch with such 
developments, laboratory technology/ies have advanced dramatically; molecular detection 
strategies have ostensibly replaced “direct morphology-based identification” and themselves 
have evolved from straightforward detection of single target(s) via PCR into next-generation 
platforms with massive resolving power that can rapidly detect whole viral genomes and 
sequence the host genome which HPVs occupy [5, 6]. 
Are we nearing the end of the road for HPV research? Have we made all reasonable 
endeavours to address this area, and should we focus our resolve and energies on alternatives, 
particularly now that we are seeing the impact of vaccination on such a scale? We would argue 
otherwise. Unfortunately, cervical cancer still continues to be a major clinical and societal 
burden, particularly in low and middle-income countries [7]. Additionally, other HPV-associated 
cancers for which there are no screening programmes are rising, including but not confined to 
oropharyngeal cancer [8, 9]. We do not have a clear idea about mechanisms of HPV 
persistence versus clearance and the precise molecular details of how certain hrHPV types can 
lead to cancer, sometimes in a short time frame. Relatively little is known about the specific 
genetic and epigenetic mutations that underpin the evolution of cervical intra-epithelial 
neoplasia (CIN) 3, nor exactly which steps have a required sequence that then further facilitate 
the transformation of CIN3 to malignancy [10, 11]. In addition, the optimal combination of 
vaccination and screening strategies will require agile thinking so that the value and efficiency of 
both can be realised in a time where shifting patterns of infection and disease will be the norm. 
A Survey to Help Define the Key Priorities for HPV Research for the 
Next 5–10 Years 
Rather than simply stating “more work/research is needed” one of the aims of this piece 
was to try to identify priorities for HPV research going forward in the next 5–10 years at this 
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crucial time. To inform this we constructed a structured survey composed of 46 HPV research 
“categories” (Fig. 1) which was sent to key opinion leaders (KOLs) who were invited to “rank” 
the categories according to what they perceived as a priority (Table 1), with 1 being highest and 
10 being lowest priority. The invitees represented various professions as summarised in Figure 
2. Invitees were also offered the opportunity to comment on what they considered could be 
barriers/issues to the research and were also given the opportunity to suggest other research 
areas that required attention which were either not included or adequately reflected in the 
survey-wording. 
Dissemination  
The initial survey was first sent to a “pilot” panel of individuals representing the above 
disciplines. The pilot panel offered key feedback/suggestions, which informed subsequent 
dissemination of a finalised questionnaire to 73 KOLs.  
Response(s) to Research Questionnaire 
We received a total of 29 responses; 25 of the surveys were utilisable for scoring, and 
the remainder were used descriptively for specific comments. 
We received responses from all 7 of the “disciplines” described earlier although those 
from epidemiologists, clinicians (particularly gynae-oncology) and basic virology were the most 
represented. The majority of responses were from KOLs based in North, South or Central 
America or Europe. Responses from those with particular expertise in conducting research in 
low- to middle-income countries (LMICs) were also obtained.  
Of the 46 categories in the survey we present those that were ranked as the first 15. 
Arguably, the first 15 categories can be grouped into three themes: (1) cervical screening, (2) 
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vaccination, (3) basic science and biobanking (Fig. 3). In the subsequent sections we discuss 
priorities in relation to the said themes. 
As not all responders added a score to each category, scores were weighted according 
to the number of responses.  
Cervical Screening 
The category considered the highest research priority was “optimal cervical screening in 
LMIC” although it was of interest that two further categories based on cervical screening 
research ranked within the top 5: “optimal cervical screening in high-income countries (HICs)” 
and “optimal screening strategies for vaccinated women.” 
Other top 15 categories related to screening included: “self-sampling to support cervical 
screening and disease management,” “improving equity of access in cervical screening” and 
“quality assurance and metrics for HPV-based screening.” 
With respect to the “top” priority a general barrier to delivery was inevitably “funding” in 
addition to responses that modelling studies will continue to be of value given the practical 
challenges of performing active research. It is beyond the scope of the present manuscript to 
consider all of the potential options for LMIC particularly given that one solution will clearly not 
“fit” all needs. However, one issue that will require careful consideration is the optimal 
combination of vaccination and screening with this representing a challenge for all settings. The 
aspiration of the HPV FASTER endeavour/group is based on the proposal of extending HPV 
vaccination programmes to women up to the age of 30 years (and potentially up to 50 in certain 
settings) in addition to at least one HPV-based screening test in women aged 30 or more [12]. 
Various modelling studies based on actual and anticipated reduction in viral and disease 
prevalence have converged on the conclusion that cervical screening of immunised women may 
involve 2–3 visits in a lifetime [13–15]. The Australian COMPASS trial will represent the first 
randomised controlled trial of HPV primary screening versus cytology in a population that 
includes females with high vaccine uptake rates [16]. While these conclusions will be of 
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undoubted and timely value to the international community, how easily the observations may be 
extrapolated and transcribed may be more challenging given: (1) the significant variability in 
cytology performance between and within countries, (2) the potential impact of HPV primary 
screening assay choice, and (3) immediate and subsequent triage strategies which again vary 
widely according to programme [17]. Thus, requirement for country-specific evaluation projects 
which take into account mixed populations of immunised and non-immunised women may be 
justified. Such projects are also likely to benefit from the incorporation of modern technologies 
related to sample taking and laboratory testing. 
Self-sampling based on the dissemination of postal testing kits, which contain swabs for 
the self-collection of exfoliated vaginal samples, has been introduced in certain settings, 
including at the programme level [18, 19]. Self-sampling has largely been directed to women 
who default from regular screening invitations [20, 21]. Such work speaks to 
“addressing/improving equity of access in cervical screening.” Certainly, the speed of 
development of self-sampling devices has accelerated considerably over the last 5 years as has 
the consideration of urine as a credible biospecimen for HPV testing [22–24]. 
There are fewer studies that have directly addressed the performance of self-sampling in 
those who do attend for cervical screening [25]. Given the accelerated progress in objective 
molecular triage strategies (see later), which could obviate the requirement to visit a clinic, this 
is arguably an under-researched area both with respect to attitudinal research and “wet,” cohort 
studies or trials. Hurdles identified by the KOLs to delivering this type of research include 
engagement and buy-in from the gynaecological community given that it may “reduce their 
income.” This “gynae scepticism” as one KOL put it may be particularly marked in settings with 
opportunistic screening programmes. Further work to quantify the extent of this scepticism (and 
its drivers) may be of value and help determine what level and type of evidence would be 
required to effect an actual change. 
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Regarding “biomarkers for risk stratification and triage of HPV infection” the perceived 
significant appetite for these in the international community has been borne out by the present 
survey. However, in terms of application, of the countries which have implemented HPV primary 
screening programmes (or pilots), the triage strategies imposed have involved cytology (with or 
without adjunctive staining), limited genotyping or a combination of both [17]. These strategies 
do not provide a binary (yes/no) answer that allow “triage”-negative women to be returned to 
routine screening. Additionally, triage strategies based on morphology and limited typing will be 
less practicable and efficacious given challenges around retention of cytology workforce and the 
impact of vaccination which will reduce the PPV of both approaches [26, 27]. Further work to 
develop and apply objective triage tests that do not require subjective interpretation and are 
unaffected by immunisation are warranted. The most evidenced candidate(s) are assays that 
are based on viral and/or cellular methylation. Methylation testing may be an effective triage tool 
to detect and characterise women at high risk of developing CIN3. The effectiveness of such 
tests in predicting CIN3 may influence the screening process in many ways, for example by 
providing an objective method to reach more accurate prognoses or by helping to avoid 
overtreatment of women with non-progressive lesions [28–31]. 
When considering quality assurance and metrics for HPV-based screening, this is a very 
translational aspect but one that does require attention. The frequently cited guidelines of Meijer 
et al. [32] from 2009 have been invaluable for the benchmarking of HPV DNA tests that are 
suitable for cervical screening. However, the guidelines are nearly 10 years old and omit certain 
elements that would be required for contemporary screening practices such as consideration 
(and relevant validation) of genotyping tests, biomarker tests, self-sampling and the influence of 
vaccination. Other key aspects of quality monitoring must incorporate performance of the test 
and subsequent management algorithms relative to significant disease within a programme, 
according to the accepted standards/key performance indicators. Again, as the pattern and 
extent of disease change in countries where vaccination has been embedded, these 
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performance indicators may well need to adapt. Suggested barriers to this type of research 
included “getting the health care services to understand that quality assurance is important” and 
issues around the accuracy/comprehensiveness of relevant data sources, access therein and 
governance, which again may be more challenging in opportunistic programmes. 
Vaccination 
“Primary disease prevention in LMIC via prophylactic vaccination (including 1-dose 
schedules)” was the second highest rated of the categories/priorities described and is in line 
with the highest rated category “optimal cervical screening in LMIC.” The reality that 80% of 
cervical cancers are diagnosed in LMIC explains this observation. Twelve years ago, when a 
number of HICs were introducing HPV vaccine programmes there was a vanishingly small 
number of LMICs that were doing the same, largely due to cost of the vaccine which may have 
been compounded by the Global Alliance on Vaccines and Immunisation (which supports 
funding of childhood vaccination programmes in LMIC) not committing resources until 2011 [33–
35]. In 2018, the situation is more encouraging; a greater number of LMICs now have HPV 
demonstration projects or programmes and the “73 Decade of Vaccines” countries are projected 
to deliver HPV vaccine programmes in the period between 2015 and 2030. The endorsement of 
multicohort vaccination of 9- to 14-year-old girls in LMIC by the WHO could also maximise 
benefits. Previously, single age cohort administration was the modus operandi for LMIC, usually 
at the lower end of the age indication (9–10 years). However, accumulated evidence, including 
that derived from modelling work, indicates that multicohort vaccination could bring about a 
reduction in cervical cancer deaths at a greater rate, as recently described [36]. The utility of 1-
dose schedules has also been demonstrated in post hoc evaluations of the vaccine trials and in 
disaggregated data from national programmes (where available) although efficacy has been 
largely shown for viral rather than disease end points [37]. The recent set-up of prospective 
randomised controlled trials which will directly address the effectiveness of reduced dose 
schedules will be of clear value and is likely to influence decision making given the cost and 
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logistical savings [38, 39]. This is relevant when we considered the respondent issues to 
barriers around vaccination which included “funding,” “governance” and “competing priorities.” 
It was also notable that “impact of vaccine on HPV infection and associated disease” was 
considered a top-5 priority, irrespective of setting. While considerable data are now available 
which have shown a significant impact on a variety of different outcome measures (infection, 
warts, herd immunity, clinical activity) [40–42] we still await data to demonstrate impact on 
cancer and also direct evidence from mixed dosing trials (where different vaccines have been 
used in schedules of >1 dose). The demonstration of vaccine efficacy links to “management and 
mitigation of perceived vaccine safety issues.” Arguably such a demonstration (including in 
LMICs) is key to supporting positive and evidence-based messages around the benefits-to-
harms ratio of the vaccines. The republic of Ireland experienced a significant drop in uptake 
(from around 87% in 2014 to approx. 50% in 2016/17) after heavyweight antivaccine lobbying, 
although recent evidence indicates that rates are now recovering [43]. However, this was after 
significant effort and explicit government support which included the creation of the HPV 
Vaccination Alliance, a group of approximately 35 separate diverse organisations, including 
women’s rights, child welfare and various health organisations, all committed to raising 
awareness of HPV vaccination. The experience in Ireland and indeed elsewhere (including 
Denmark, Romania and Japan) [44–46] shows how rapidly successful campaigns can founder 
and strengthens the case for applied high-quality research that “explores barriers to vaccine 
participation.” Consistent feedback from KOLs on the hurdles of delivering such information was 
based around the challenges and governance of gaining access to unvaccinated females (in 
various settings) with whom to conduct qualitative research. A further interesting comment was 
that for traction, the results of such studies required “acceptance by biologic scientists and 
physicians of results and implementation plans.” 
Determination of vaccine effectiveness includes gaining a greater understanding of 
“immunogenicity and long-term protection” in order to inform pragmatic strategies/schedules 
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going forward and to support key educational messages to best engage the public. However, 
consistent with feedback, ease of delivery will vary according to setting. Countries with 
centralised cancer registries and national cervical screening databases where accurate 
immunisation data can be linked (with due process of governance) to other relevant health care 
data sets are in the minority including in HICs. Potentially, the creation of “international 
databases” (to quote from one KOL) that could be “used to determine health disparities” and 
determine differential impacts on particular ethnic and societal groups would be of value. Like 
many other categories, research exploring the impact of and barriers to vaccination was 
perceived to be hampered by lack of funding. While industry has played a crucial part in 
supporting and funding long-term efficacy and safety trials, the conflict that this presents, 
particularly to the antivaccine community, can limit and subvert the conclusions of these studies. 
One responder indicated that “ideally studies must remain absolutely free of conflicts to assure 
trustworthiness.” 
Therapeutic vaccination was also included in the first 15 categories. While clearly of 
value there is to date no licensed therapeutic vaccine or antiviral that carries a specific 
indication for HPV-associated disease. Therapeutic vaccines may be based on live vectors, 
protein/peptide, whole cell(s) or nucleic acid. An increasing number of vaccines have now 
reached clinical trial/application, most prominently for nucleic acid-based vaccines. Encouraging 
results in phase 2 clinical trials have been observed in patients with HPV16- and HPV18-
associated CIN and also in vulval disease [47]. In addition to the generation of new candidate 
therapeutic vaccines and assessment of their efficacy in trials, several strategies that could 
enhance the vaccine effect require investigation. Such strategies need to include improvement 
in the uptake and presentation of HPV antigens in dendritic cells [48, 49]. Furthermore, optimal 
use of a vaccine in combination with other therapies including chemo-radiotherapy and 
immunological adjuvants is an area that would benefit from additional research and is consistent 
with the general endeavour in health care to deliver personalised/stratified management for 
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patients [47, 50, 51]. There was a relatively small amount of feedback related to challenges 
around delivering research to develop this particular field although 2 respondents indicated the 
importance of performing basic science to understand and define the key immunological 
effectors of disease regression, as well as robust clinical trials. These comments are consistent 
with those articulated in an excellent review of therapeutic vaccines by Cheng et al. [47], who 
stated that “a deeper knowledge of the tumor micro-environments also holds great potential for 
improving therapeutic vaccines.” 
Basic Science and Biobanking 
The aspect of basic science relating to HPV which was considered the highest priority 
was molecular and cellular biology – transformation. Key effectors and players critical to the 
transformation process are challenging to trial in patient settings as the threshold for treatment 
is generally CIN2+, a heterogeneous lesion, the majority of which will regress and as discussed 
more than half of CIN3 (a greater proxy of significant disease) will regress [52]. Models to study 
HPV infection and transformation are clearly important, thus the development and access to 
such models are crucial to understanding basic mechanisms key to viral life cycle and 
transformation, in addition to helping to determine the influence of external agents/therapeutics. 
The development and enhancement of model systems was identified as a missing priority area 
in the survey. Creating such models is challenging as HPV is obligated to complete its life cycle 
in human differentiated epithelium which is clearly complex to recreate. The most established 
models involve the culture of HPV-infected keratinocytes, directly derived from a human lesion 
(e.g., W12) or transfected artificially (e.g., NIKS) in organotypic raft cultures. Raft cultures 
enable epithelial differentiation to be capitulated at least to an extent in vitro [53, 54]. These 
systems have been used extensively although with a bias to those infected with HPV16 and 
HPV18.  
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Animal models arguably offer a more holistic system in which to monitor infection and 
disease longitudinally, particularly given the natural history of lesion development which can 
take several years and the fundamental influence of immune responses. The cottontail rabbit 
papillomavirus and the rabbit oral papillomavirus have yielded important discoveries including 
insights into the features/hallmarks of viral latency and how this links to clinical manifestations 
[54]. The mouse papillomavirus MmuPV has also been used recently to study the influence of 
immunological factors on HPV infection and associated lesions, and transgenic models of 
disease have provided insights into the influence of external factors such as hormones and UV 
irradiation on disease [55]. Compared to models of cervical disease, models of other HPV-
associated cancers are rarer and less established. Given the increase in non-cervical cancers, 
this is an area that requires attention as was pointed out by a survey responder. 
The influence of the microbiome on a diverse range of health outcomes including 
physical and mental health has been one of the most fertile and interesting areas of 
microbiological research in the last decade. In relation to HPV infection, data indicate that 
diversity in the vaginal mucosa is independently associated with a lower risk of disease 
progression, whereas a reduced relative component of lactobacilli and domination of strict 
anaerobes is associated with worse outcomes [56, 57]. Lactobacilli support an acidic vaginal 
environment and studies, including large population-based series, have indicated that low 
vaginal pH (<5) is associated with a lower risk of HPV positivity. Additionally, Motevaseli et al. 
[58] showed that lactobacilli can exert a cytotoxic effect on Hela cells (cancer cell line driven by 
HPV18) independently of lactate and also pH, an effect not observed in a “normal” non-infected 
epithelial cell line, suggesting that other factors in addition to pH may add protective 
characteristics of lactobacilli. Such observations have been reinforced by more recent work 
which demonstrated the inhibitory effect of lactobacillus supernatants on CaSki cells (a cancer 
cell line which contains HPV16) [59]. This work has brought about consideration of probiotic and 
prebiotic preparations to modify the vaginal microbiota; the future application of these ideas in 
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trial settings will provide essential clinical data as to the effectiveness of the approach. The bulk 
of studies which have assessed the influence of the wider microbiological context and HPV 
have focussed on the vagina and implications for cervical disease. There are relatively few data 
that have looked at the microbiome to determine its potential influence on other HPV-associated 
cancers including oropharyngeal cancer. This may well be an area that deserves increased 
attention given that small, proof-of-concept studies indicate that the composition of the salivary 
microbiome may reflect discrete clinical and aetiological states [60]. Few issues with respect to 
the microbiome were raised by KOLs other than a call to define the term “microbiome” in a bid 
for accuracy and consistency and to make between-study comparison more robust. 
“Access to samples and optimal biobanking for the future” was identified as a priority 
area, and fundamentally well-annotated biobanks with access to clinical data will support the 
various research priorities discussed above. Issues raised included “maintenance” and “costs.” 
Additionally, storage and manipulation of routinely taken clinical samples to deliver research 
that demands high-quality RNA can be challenging. Consequently, research which supports the 
enhancement of sample stability and maximal yield and quality of derivatives is important to 
make the best use of biobanks in the future. International sharing of best practice and protocols 
will also be of value in achieving this.  
Ensuring appropriate and robust governance is in place also absolutely essential, and it 
can take time to identify and secure the relevant permissions, particularly as there are generally 
a number of entities who must be engaged with in addition to the research ethical committee. 
As the set-up of biobanks requires considerable infrastructure, core funding to support this even 
for a fixed period is of help. Thereafter, revenue can be generated as a function of requests for 
access to samples. While this can help sustain archives, it is not generally sufficient for 
complete maintenance, particularly as the frequency and nature of requests cannot be 
accurately predicted. Complimentary funding from grants is often required as well as core 
funding from national resources. One issue raised with respect to the latter is the potential lack 
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of “political awareness” of the requirement for biobanks. Basic and applied studies would benefit 
from access to well-annotated samples from the cervical screening programmes with long-term 
follow-up information which would allow an accurate evaluation of new markers and associated 
interventions. Another added benefit of access to such samples/information would be the 
potential to link to records that allow the influence of the marker/modality under study on a 
variety of HPV-related (or putatively related) cancers. Certainly, given the increase in self-
sampling in the current screening programmes, biobanks that contain a heterogeneity of both 
clinician and self-taken samples would be valuable including those from studies where matched 
samples (clinician vs. self) have been collected. International efforts to support both hard 
protocols (specimen manipulation) and soft protocols (linkage and governance considerations) 
for prospective biobanking could be game changing with respect to the speed of how new 
developments are assessed and implemented [61]. 
Additional Areas for Research 
Table 2 summarises the additional comments we received from responders (n = 7) as to 
“other suggestions for the future.” These areas were perceived as either absent from the 
original questionnaire or not covered explicitly enough. A total of 14 suggestions were 
articulated: 3 related to screening, 6 vaccination and 5 addressed to basic science/biobanking. 
Regarding screening, 2 of the 3 comments, again, described the requirement to deliver 
research that would support improvements in LMICs. The final comment related to a screening 
test for oropharyngeal cancer, and this indeed reconciles with the significant global increase in 
oropharyngeal cancer in the last decade [8]. An “early warning” test for what can be a highly 
morbid disease is clearly worth consideration; however, one of the challenges around this is the 
nature of the intervention in view of a positive test, given that there is no clear precursor phase 
for oropharyngeal squamous cell carcinoma. 
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The additional comments on vaccination talk to some of the earlier discussion around the 
requirement for more readily affordable vaccines and associated dosing schedules to support 
use in LMICs, as does the delivery of research to improve vaccination rates by focussing on 
behavioural interventions. Research into the use of vaccine for broader/off-label indications was 
also suggested by 2 separate responders including for “older” age groups and for those 
potentially at greater risk of disease including those previously treated for high-grade CIN, men 
who have sex with men and “underscreened” populations. Arguably some of these research 
proposals have already translated into implementation, for example, in the UK a targeted 
vaccination programme for MSMs was piloted initially in 2016 with full implementation in place in 
Northern Ireland, Scotland and Wales. Furthermore, vaccination of older age groups is 
consistent with the ethos of HPV FASTER, as described earlier [12]. Any potential therapeutic 
benefit of the prophylactic vaccine would benefit from further comprehensive research as 
current evidence is relatively ambiguous and largely based on single-arm, small observational 
trials. The comments on additional developments for basic science spoke to the requirement for 
specific sample sets to be accommodated in biobanks and the use of models, including models 
of non-cervical disease to support the identification and assessment of new therapies. 
Concluding Remarks 
Research on HPV has exerted a significant global impact on the burden of infection and 
disease in addition to providing insight into key mechanistic processes fundamental for lesion 
and cancer development that have a broader reach. 
The multidisciplinary nature of research to date has undoubtedly contributed to these 
outcomes. While we have argued that requirement for further HPV research is essential to 
improve morbidity, globally how to address funding constraints will be an inevitable challenge. 
An interesting refrain from a number of responders was that strategically, funders may be less 
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inclined to fund HPV research given the availability and success of vaccine – this was perhaps 
articulated most succinctly by the comment that “the funding crunch is to some extent a 
reflection of our own success.” The case for continued funding for HPV-based research requires 
concerted support from the international community to ensure it does not slip from the agenda 
and so that opportunities for successful collaborations are identified. Such collaborations may 
not just be confined to practical projects, but also exercises that make the most of existing 
sample and data sets. While there are clear governance constraints and processes that are 
required to permit this, the said processes should balance the potential harms to benefits in 
order not to preclude or significantly delay relevant contemporary research that will directly 
inform the next stage of service improvement. As one responder put it: “Arguably, HPV research 
has been one of the most successful areas in medicine and public health” – now we must be 
careful not to drop the ball or to throw obstacles in its path. 
Finally, while we happily acknowledge the theme of this issue, to contextualise the 
developments in HPV research, with respect to geological timescales is challenging given that 
within the three million year quarternary period, the time of humankind is too diminutive to be 
visible! However, if we refine our perspective to the Jurassic age, perhaps we should reflect that 
the “dinosaur renaissance,” a revolution which started in the late 1960s, inspired concerted and 
renewed interest in dinosaurs within academia and popular culture after sight of evidence which 
indicated dinosaurs may have been warm-blooded, intelligent active animals, rather than 
plodding cold-bloods as had been the earlier consensus. The said renaissance brought about a 
seismic shift in thinking on all fundamental aspects of dinosaur biology. Researchers of a 
certain vintage take heart (!) and positive ownership of the dinosaur epithet to exert your warm-
blooded intelligent active selves to meet the challenges of the new epoch in HPV research. 
Acknowledgements 
  18 
 
 
We would like to thank the following individuals for their welcome and expert 
contributions: Alex Castanon, Andrew Macdonald, Barbara Moscicki, Christopher Crum, Cosette 
Wheeler, David Mesher, Diane Harper, Eduardo Franco, Francesca Carozzi, Gary Clifford, Gina 
Ogilvie, Laurie Smith, Gregory Zimmet, Hans Berkhof, Iain Morgan, Jesper Bonde, Joe 
Monsonego, Jo Waller, Jose Jeronimo, Kate Soldan, Kevin Pollock, Lawrence Banks, Luisa 
Villa, Marc Arbyn, Matejka Rebolj, Paul Lambert, Pekka Niemenen, Peter Hillemans, Sheila 
Graham and Sylvia Franceschi.  
Disclosure Statement 
K.C. (non-personal): K.C.’s institution has received funding for research or consumables 
to support research in the last 3 years from Qiagen, Hologic, Selfscreen, GeneFirst, 
Euroimmun, Cepheid, Genomica, LifeRiver. A.L.: no conflict of interest. B.N.: no conflict of 
interest. 
Author Contributions 
K.C.: involved in survey construction and initial testing, survey dissemination, response 
collation and manuscript preparation and refinement. A.L.: involved in survey construction and 
manuscript preparation, refinement and ultimate review. 
B.N.: involved in survey construction and initial testing, survey dissemination, response 
collation and manuscript preparation and refinement. 
References 
1 Gissmann L, Boshart M, Dürst M, Ikenberg H, Wagner D, zur Hausen H. Presence of 
human papillomavirus in genital tumors. J Invest Dermatol. 1984 Jul;83(1 Suppl):26s–8s. 
  19 
 
 
2 Syrjänen KJ, Syrjänen SM. Human papilloma virus (HPV) infections related to cervical 
intraepithelial neoplasia (CIN) and squamous cell carcinoma of the uterine cervix. Ann 
Clin Res. 1985;17(2):45–56. 
3 Gissmann L. Human papillomaviruses and genital cancer [R]. Semin Cancer Biol. 1992 
Oct;3(5):253–61. 
4 zur Hausen H. Papillomaviruses in the causation of human cancers - a brief historical 
account. Virology. 2009 Feb;384(2):260–5. 
5 Poljak M, Kocjan BJ, Oštrbenk A, Seme K. Commercially available molecular tests for 
human papillomaviruses (HPV): 2015 update. J Clin Virol. 2016 Mar;76 Suppl 1:S3–13. 
6 Mirabello L, Clarke MA, Nelson CW, Dean M, Wentzensen N, Yeager M, et al.; NCI HPV 
Workshop. The Intersection of HPV Epidemiology, Genomics and Mechanistic Studies of 
HPV-Mediated Carcinogenesis. Viruses. 2018 Feb;10(2):E80. 
7 Mezei AK, Armstrong HL, Pedersen HN, Campos NG, Mitchell SM, Sekikubo M, et al. 
Cost-effectiveness of cervical cancer screening methods in low- and middle-income 
countries: A systematic review. Int J Cancer. 2017 Aug;141(3):437–46. 
8 Hussein AA, Helder MN, de Visscher JG, Leemans CR, Braakhuis BJ, de Vet HC, et al. 
Global incidence of oral and oropharynx cancer in patients younger than 45 years versus 
older patients: A systematic review. Eur J Cancer. 2017 Sep;82:115–27. 
9 Carlander AF, Grønhøj Larsen C, Jensen DH, Garnæs E, Kiss K, Andersen L, et al. 
Continuing rise in oropharyngeal cancer in a high HPV prevalence area: A Danish 
population-based study from 2011 to 2014. Eur J Cancer. 2017 Jan;70:75–82. 
10 Nedjai B, Reuter C, Ahmad A, Banwait R, Warman R, Carton J, et al. Molecular 
progression to cervical precancer, epigenetic switch or sequential model? Int J Cancer. 
2018 Apr;143(7):1720–30. ; Epub ahead of print. 
  20 
 
 
11 Kriek JM, Jaumdally SZ, Masson L, Little F, Mbulawa Z, Gumbi PP, et al. Female genital 
tract inflammation, HIV co-infection and persistent mucosal human papillomavirus (HPV) 
infections. Virology. 2016 Jun;493:247–54. 
12 Bosch FX, Robles C, Díaz M, Arbyn M, Baussano I, Clavel C, et al. HPV-FASTER: 
broadening the scope for prevention of HPV-related cancer. Nat Rev Clin Oncol. 2016 
Feb;13(2):119–32. 
13 Landy R, Windridge P, Gillman MS, Sasieni PD. What cervical screening is appropriate 
for women who have been vaccinated against high risk HPV? A simulation study. Int J 
Cancer. 2018 Feb;142(4):709–18. 
14 Pedersen K, Burger EA, Nygård M, Kristiansen IS, Kim JJ. Adapting cervical cancer 
screening for women vaccinated against human papillomavirus infections: The value of 
stratifying guidelines. Eur J Cancer. 2018 Mar;91:68–75. 
15 Canfell K. Cervical screening in HPV-vaccinated populations. Climacteric. 2018 
Jun;21(3):227–34. 
16 Canfell K, Saville M, Caruana M, Gebski V, Darlington-Brown J, Brotherton J, et al. 
Protocol for COMPASS: A randomised controlled trial of primary HPV testing versus 
cytology screening for cervical cancer in HPV-unvaccinated and vaccinated women aged 
25–69 years living in Australia [Erratum in: BMJ Open. 2018 Mar 8;8(3):e016700corr1]. 
BMJ Open. 2018 Jan;8(1):e016700. 
17 Cuschieri K, Ronco G, Lorincz A, Smith L, Ogilvie G, Mirabello L, et al. Eurogin roadmap 
2017: triage strategies for the management of HPV-positive women in cervical screening 
programs. Int J Cancer. 2018 Aug;143(4):735–45. 
18 Lam JU, Rebolj M, Møller Ejegod D, Pedersen H, Rygaard C, Lynge E, et al. Human 
papillomavirus self-sampling for screening nonattenders: opt-in pilot implementation with 
electronic communication platforms. Int J Cancer. 2017 May;140(10):2212–9. 
  21 
 
 
19 Enerly E, Bonde J, Schee K, Pedersen H, Lönnberg S, Nygård M. Self-Sampling for 
Human Papillomavirus Testing among Non-Attenders Increases Attendance to the 
Norwegian Cervical Cancer Screening Programme. PLoS One. 2016 
Apr;11(4):e0151978. 
20 Verdoodt F, Jentschke M, Hillemanns P, Racey CS, Snijders PJ, Arbyn M. Reaching 
women who do not participate in the regular cervical cancer screening programme by 
offering self-sampling kits: a systematic review and meta-analysis of randomised trials. 
Eur J Cancer. 2015 Nov;51(16):2375–85. 
21 Lim AW, Hollingworth A, Kalwij S, Curran G, Sasieni P. Offering self-sampling to cervical 
screening non-attenders in primary care. J Med Screen. 2017 Mar;24(1):43–9. 
22 Pathak N, Dodds J, Zamora J, Khan K. Accuracy of urinary human papillomavirus testing 
for presence of cervical HPV: Systematic review and meta-analysis. BMJ. 2014 
Sep;349:g5264. 
23 Van Keer S, Tjalma WA, Pattyn J, Biesmans S, Pieters Z, Van Ostade X, et al. Human 
papillomavirus genotype and viral load agreement between paired first-void urine and 
clinician-collected cervical samples. Eur J Clin Microbiol Infect Dis. 2018 May;37(5):859–
69. 
24 Leinonen MK, Schee K, Jonassen CM, Lie AK, Nystrand CF, Rangberg A, et al. Safety 
and acceptability of human papillomavirus testing of self-collected specimens: A 
methodologic study of the impact of collection devices and HPV assays on sensitivity for 
cervical cancer and high-grade lesions. J Clin Virol. 2018 Feb-Mar;99-100:22–30. 
25 Stanczuk G, Baxter G, Currie H, Lawrence J, Cuschieri K, Wilson A, et al. Clinical 
validation of hrHPV testing on vaginal and urine self-samples in primary cervical 
screening (cross-sectional results from the Papillomavirus Dumfries and Galloway-
PaVDaG study). BMJ Open. 2016 Apr;6(4):e010660. 
  22 
 
 
26 Palmer TJ, McFadden M, Pollock KG, Kavanagh K, Cuschieri K, Cruickshank M, et al. 
HPV immunisation and cervical screening—confirmation of changed performance of 
cytology as a screening test in immunised women: a retrospective population-based 
cohort study. Br J Cancer. 2016 Mar;114(5):582–9. 
27 Bhatia R, Kavanagh K, Cubie HA, Serrano I, Wennington H, Hopkins M, et al. Use of 
HPV testing for cervical screening in vaccinated women—Insights from the SHEVa 
(Scottish HPV Prevalence in Vaccinated Women) study. Int J Cancer. 2016 
Jun;138(12):2922–31. 
28 De Strooper LM, Berkhof J, Steenbergen RD, Lissenberg-Witte BI, Snijders PJ, Meijer 
CJ, et al. Cervical cancer risk in HPV-positive women after a negative FAM19A4/mir124-
2 methylation test: A post hoc analysis in the POBASCAM trial with 14 year follow-up. Int 
J Cancer. 2018 Sep;143(6):1541–8. 
29 Lorincz AT. Virtues and Weaknesses of DNA Methylation as a Test for Cervical Cancer 
Prevention. Acta Cytol. 2016;60(6):501–12. 
30 Kelly HA, Chikandiwa A, Warman R, Segondy M, Sawadogo B, Vasiljevic N, et al. 
Associations of human gene EPB41L3 DNA methylation and cervical intraepithelial 
neoplasia in women living with HIV-1 in Africa. AIDS. 2018 Sep;32(15):2227–36. 
31 Luttmer R, De Strooper LM, Dijkstra MG, Berkhof J, Snijders PJ, Steenbergen RD, et al. 
FAM19A4 methylation analysis in self-samples compared with cervical scrapes for 
detecting cervical (pre)cancer in HPV-positive women. Br J Cancer. 2016 
Aug;115(5):579–87. 
32 Meijer CJ, Berkhof J, Castle PE, Hesselink AT, Franco EL, Ronco G, et al. Guidelines for 
human papillomavirus DNA test requirements for primary cervical cancer screening in 
women 30 years and older. Int J Cancer. 2009 Feb;124(3):516–20. 
33 Gallagher KE, LaMontagne DS, Watson-Jones D. Status of HPV vaccine introduction 
and barriers to country uptake. Vaccine. 2018 Aug;36(32 32 Pt A):4761–7. 
  23 
 
 
34 Sabeena S, Bhat PV, Kamath V, Arunkumar G. Global human papilloma virus vaccine 
implementation: An update. J Obstet Gynaecol Res. 2018 Jun; 44(6):989–97. 
35 Harper DM, DeMars LR. HPV vaccines – A review of the first decade [Erratum in: 
Gynecol Oncol. 2017 Nov;147(2)]. Gynecol Oncol. 2017 Jul;146(1):196–204. 
36 Jit M, Brisson M. Potential lives saved in 73 countries by adopting multi-cohort 
vaccination of 9-14-year-old girls against human papillomavirus. Int J Cancer. 2018 
Jul;143(2):317–23. 
37 Kreimer AR, Struyf F, Del Rosario-Raymundo MR, Hildesheim A, Skinner SR, Wacholder 
S, et al.; Costa Rica Vaccine Trial Study Group Authors; PATRICIA Study Group 
Authors; HPV PATRICIA Principal Investigators/Co-Principal Investigator Collaborators; 
GSK Vaccines Clinical Study Support Group. Efficacy of fewer than three doses of an 
HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica 
Vaccine and PATRICIA Trials. Lancet Oncol. 2015 Jul;16(7):775–86. 
38 Sampson JN, Hildesheim A, Herrero R, Gonzalez P, Kreimer AR, Gail MH. Design and 
statistical considerations for studies evaluating the efficacy of a single dose of the human 
papillomavirus (HPV) vaccine. Contemp Clin Trials. 2018 May;68:35–44. 
39 Franceschi S, Clifford GM, Baussano I. Options for design of real-world impact studies of 
single-dose vaccine schedules. Vaccine. 2018 Aug;36(32 32 Pt A):4816–22. 
40 Kavanagh K, Pollock KG, Cuschieri K, Palmer T, Cameron RL, Watt C, et al. Changes in 
the prevalence of human papillomavirus following a national bivalent human 
papillomavirus vaccination programme in Scotland: a 7-year cross-sectional study. 
Lancet Infect Dis. 2017 Dec;17(12):1293–302. 
41 Korostil IA, Ali H, Guy RJ, Donovan B, Law MG, Regan DG. Near elimination of genital 
warts in Australia predicted with extension of human papillomavirus vaccination to males. 
Sex Transm Dis. 2013 Nov;40(11):833–5. 
  24 
 
 
42 Cruickshank ME, Pan J, Cotton SC, Kavanagh K, Robertson C, Cuschieri K, et al. 
Reduction in colposcopy workload and associated clinical activity following human 
papillomavirus (HPV) catch-up vaccination programme in Scotland: an ecological study. 
BJOG. 2017 Aug;124(9):1386–93. 
43 Corcoran B, Clarke A, Barrett T. Rapid response to HPV vaccination crisis in Ireland. 
Lancet. 2018 May;391(10135):2103. 
44 Maier C, Maier T, Neagu CE, Vlădăreanu R. Romanian adolescents’ knowledge and 
attitudes towards human papillomavirus infection and prophylactic vaccination. Eur J 
Obstet Gynecol Reprod Biol. 2015 Dec;195:77–82. 
45 Suragh TA, Lamprianou S, MacDonald NE, Loharikar AR, Balakrishnan MR, Benes O, 
Hyde TB, McNeil MM. Cluster anxiety-related adverse events following immunization 
(AEFI): An assessment of reports detected in social media and those identified using an 
online search engine. Vaccine. 2018 Sep 25;36(40):5949–54. 
46 Hanley SJ, Yoshioka E, Ito Y, Kishi R. HPV vaccination crisis in Japan [Erratum in: 
Lancet. 2015 Jul;386(9990):248]. Lancet. 2015 Jun 27;385(9987):2571. 
47 Cheng MA, Farmer E, Huang C, Lin J, Hung CF Wu TC. Therapeutic DNA vaccines for 
human papillomavirus and associated diseases. Hum Gene Ther. 2018 Sep;29(9):971–
96. 
48 Galliverti G, Tichet M, Domingos-Pereira S, Hauert S, Nardelli-Haefliger D, Swartz MA, 
Hanahan D, Galliverti G, Tichet M, Domingos-Pereira S, Hauert S, Nardelli-Haefliger D, 
Swartz MA, Hanahan D, Wullschleger S. Nanoparticle conjugation of human 
papillomavirus 16 E7-long peptides enhances therapeutic vaccine efficacy against solid 
tumors in mice. Cancer Immunol Res. 2018 Nov;6(11):1301–13. 
49 Ilyinskii PO, Kovalev GI, O’Neil CP, Roy CJ, Michaud AM, Drefs NM, et al. Synthetic 
vaccine particles for durable cytolytic T lymphocyte responses and anti-tumor 
immunotherapy. PLoS One. 2018 Jun;13(6):e0197694. 
  25 
 
 
50 Cordeiro MN, De Lima RC, Paolini F, Melo AR, Campos AP, Venuti A, et al. Current 
research into novel therapeutic vaccines against cervical cancer. Expert Rev Anticancer 
Ther. 2018 Apr;18(4):365–76. 
51 Li J, Chen S, Ge J, Lu F, Ren S, Zhao Z, et al. A novel therapeutic vaccine composed of 
a rearranged human papillomavirus type 16 E6/E7 fusion protein and Fms-like tyrosine 
kinase-3 ligand induces CD8+ T cell responses and antitumor effect. Vaccine. 2017 
Nov;35(47):6459–67. 
52 Tainio K, Athanasiou A, Tikkinen KA, Aaltonen R, Cárdenas J, Hernándes, et al. Clinical 
course of untreated cervical intraepithelial neoplasia grade 2 under active surveillance: 
Systematic review and meta-analysis. BMJ. 2018 Feb;360:k499. 
53 Christensen ND, Budgeon LR, Cladel NM, Hu J. Recent advances in preclinical model 
systems for papillomaviruses. Virus Res. 2017 Mar;231:108–18. 
54 Doorbar J. Model systems of human papillomavirus-associated disease. J Pathol. 2016 
Jan;238(2):166–79. 
55 Cladel NM, Budgeon LR, Balogh KK, Cooper TK, Hu J, Christensen ND. A novel pre-
clinical murine model to study the life cycle and progression of cervical and anal 
papillomavirus infections. PLoS One. 2015 Mar;10(3):e0120128. 
56 Kyrgiou M, Mitra A, Moscicki AB. Does the vaginal microbiota play a role in the 
development of cervical cancer? Transl Res. 2017 Jan;179:168–82. 
57 Zhang C, Liu Y, Gao W, Pan Y, Gao Y, Shen J, et al. The direct and indirect association 
of cervical microbiota with the risk of cervical intraepithelial neoplasia. Cancer Med. 2018 
May;7(5):2172–9. 
58 Motevaseli E, Shirzad M, Akrami SM, Mousavi AS, Mirsalehian A, Modarressi MH. 
Normal and tumour cervical cells respond differently to vaginal lactobacilli, independent 
of pH and lactate. J Med Microbiol. 2013 Jul;62(Pt 7):1065–72. 
  26 
 
 
59 Wang KD, Xu DJ, Wang BY, Yan DH, Lv Z, Su JR. Inhibitory Effect of Vaginal 
Lactobacillus Supernatants on Cervical Cancer Cells. Probiotics Antimicrob Proteins. 
2018 Jun;10(2):236–42. 
60 Wolf A, Moissl-Eichinger C, Perras A, Koskinen K, Tomazic PV, Thurnher D. The salivary 
microbiome as an indicator of carcinogenesis in patients with oropharyngeal squamous 
cell carcinoma: A pilot study. Sci Rep. 2017 Jul;7(1):5867. 
61 Samuels S, Balint B, von der Leyen H, Hupé P, de Koning L, Kamoun C, et al. Precision 
medicine in cancer: challenges and recommendations from an EU-funded cervical cancer 
biobanking study. Br J Cancer. 2016 Dec;115(12):1575–83. 
Appendix after References (Editorial Comments) 
 
Legend(s) 
Fig. 1. Full questionnaire sent to key opinion leaders. 
Fig. 2. Professional “groupings” of the key opinion leaders who responded to the survey. 
Fig. 3. The main three research “themes” identified as priorities for development: (1) cervical 
screening, (2) vaccination and (3) basic science and biobanking. 
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Table 1. Research priorities identified by KOLs (last response June 2018) who were invited to score 46 HPV-related research 
categories as detailed in Figure 1 
  
  
Research category Ranking 
  
  
Optimal cervical screening in LMICs 01 
Primary disease prevention in LMICs via prophylactic vaccination (including 1-dose schedules) 02 
Impact of vaccine on HPV infection and associated disease 03 
Optimal cervical screening in HICs 04 
Optimal screening strategies for vaccinated women 05 
Access to samples and optimal biobanking for the future 06 
Self-sampling to support cervical screening and disease management 07 
Management of (and mitigation against) perceived safety issues with the HPV vaccine 08 
Primary disease prevention in HICs via prophylactic vaccination 09 
Exploring barriers to vaccination participation 10 
Biomarkers for the risk stratification and triage of HPV infection 11 
Immunogenicity of vaccines and long-term protection 12 
Therapeutic vaccination 13 = 
Addressing/improving equity of access in cervical screening 13 = 
Quality assurance and metrics for HPV-based screening 14 = 
HPV and the microbiome 14 = 
Viral molecular and cellular biology – transformation 15 
  
  
Ranking is based on a total of 25 returned surveys. Categories with the same ranking are shown by the 
score followed by =. KOLs, key opinion leaders; LMICs, low- and middle-income countries; HICs, high-
income countries. The three main research “themes” cervical screening, vaccination and basic science are 
represented in white, light grey and grey cells, respectively. 
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Table 2. Additional areas for research perceived by responders as not covered or not comprehensively covered in the questionnaire 
  
  
Research theme Comment 
  
  
Screening Development of an inexpensive, rapid cervical cancer screening test that could be used in lower-
income countries and would be superior to VIA 
Screening Reduction of cervical cancer risk via prophylactic cryoablation of the squamocolumnar junction in 
low-resource settings 
Screening Development of a screening test for early detection of HPV-related oropharyngeal cancer 
Vaccination Evaluating the efficacy of a 1-dose regimen with nonavalent vaccine 
Vaccination Development of additional HPV vaccines that are less expensive and easier to transport and 
deliver, which would particularly help low- and lower middle-income countries 
Vaccination Research on public health policy approaches that could mitigate the effects of false attributions of 
harm associated with HPV vaccination; this would entail both prevention efforts in advance of the 
roll-out of vaccination and rapid response efforts to limit damage after a false claim has been made 
Vaccination Ongoing behavioural and social science research to develop messaging and behavioural 
interventions targeted at improving vaccination rates, particularly in countries like the USA that do 
not have national vaccination policies; this research needs to be multilevel, addressing youth, 
parents, health care providers, health systems and public health policy 
Vaccination Use of vaccinations at older ages to change screening strategies for older (uninfected) women 
Vaccination HPV vaccines in high-risk groups of adult women and men such as women previously treated for 
high-grade CIN, immunocompromised women and men, MSM and underscreened populations 
Basic science/biobanking HPV strains, especially immune mechanisms/differences 
Basic science/biobanking Accessing some types of samples from biobanks could also be an issue 
Basic science/biobanking “Other anti-HPV therapies," e.g. immunotherapeutics, as these are not strictly antivirals, which 
implies drugs 
Basic science/biobanking Relight the idea that looking at replication and blocking it is a viable therapeutic approach to treating 
many HPV+ cancers 
Basic science/biobanking The one thing that was missing in the survey was models; There are a few PDX models out there 
now for HPV16+ OPSCC, and we are looking at these and demonstrating circular replicating 
genomes; therefore, we have the targets and we have a model to test them, but there are not many 
HPV+ OPSCC tumours available; most of them are provided by academic colleagues 
  
  
The above comments were collated from a total of 7 responders. MSM, ■■■■■; PDX, ■■■■■; OPSCC, oropharyngeal 
squamous cell cancer. Colour coding for general themes is as previously (white = screening, light grey = vaccination and grey = 
basic science and biobanking). 
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